In patients with metastatic melanoma under ipilimumab (anti-CTLA4) therapy, GPR171 expression in melanoma was considerably increased upon ipilimumab and its expression is significantly higher in responders than non-responders27. Here, GPR171 is linked to metastatic melanoma.